Drugs / Recombinant Human Adenovirus Type 5 Injection
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05664139 | Feb 2023 → Dec 2024 | melanoma | Fujian Cancer Hospital | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Human Adenovirus Type 5 Injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05664139 ↗ |
| Route | Other | “inject 1ml into the tumor each time” NCT05664139 ↗ |